Detection of KRAS mutation at codon-12 and codon-13 associate with poor prognosis in colorectal cancer patients

Main Article Content

Namphon Klaewkla
Sarawut Chantra
Chanwit Maneenin
Parichart Pinyosri
Surasak Wanram


Colorectal cancer (CRC) associated with KRAS mutations relevance to clinical outcome of progression especially for codon mutation remain unclear, clinically. Thus this study aimed to detect KRAS mutations on specific codon-12 and codon-13. DNA extraction was performed from 40 formalin-fixed paraffin-embedded (FFPE) tissues. The KRAS codon-12 and codon-13 mutations were detected by quantitative multiplex real-time PCR consisting of seven primers of G12A, G12D, G12R, G12C, G12S, G12V, and G13D, specifically. Our results showed mutation of codon-12 at 37.5% (15/40 cases), especially for 86.7% (13/15 cases) were found G12D, G12V and G12R mutation for 40%, 40% and 6.67%, respectively. On the other hand, the codon-13 mutation found only G13D at 20% (3/15 cases). The present findings showed a statistically significant difference between KRAS mutations with lymph node metastases (p-value = 0.004), and mucosal lymphoma with other tumor types (p-value = 0.016). We noticed that KRAS mutations are associated with codon-12 and codon-13 and relevanced to prognostic outcomes of CRC patients on lymph node metastases as well as histological types. However, increased samples, novel prognostic biomarkers and more specific clinical information could be further explored to the clinical molecular biomarkers for monitoring and treatments.

Article Details

How to Cite
Klaewkla N, Chantra S, Maneenin C, Pinyosri P, Wanram S. Detection of KRAS mutation at codon-12 and codon-13 associate with poor prognosis in colorectal cancer patients. Arch AHS [Internet]. 2023 Jul. 17 [cited 2024 May 28];35(2):19-24. Available from:
Original article


Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 2021; 71(3): 209-49.

Lohsiriwat V, Chaisomboon N, Pattana-Arun J. Current colorectal cancer in Thailand. Ann Coloproctol 2020; 36(2): 78-82.

Simanshu DK, Nissley DV, McCormick F. RAS proteins and their regulators in human disease. Cell 2017; 170(1): 17-33.

Ciardiello D, Maiorano BA, Martinelli E. Targeting KRASG12C in colorectal cancer: the beginning of a new era. ESMO Open 2023; 8(1): 100745.

Plangger A, Rath B, Stickler S, Hochmair M, Lang C, Weigl L, et al. Cytotoxicity of combinations of the pan-KRAS SOS1 inhibitor BAY-293 against pancreatic cancer cell lines. Discover Oncology 2022; 13(1): 84.

Plesec TP, Hunt JL. KRAS mutation testing in colorectal cancer. Adv Anat Pathol 2009; 16(4): 196-203.

Siegel RL, Miller KD, Goding Sauer A, Fedewa SA, Butterly LF, Anderson JC, et al. Colorectal cancer statistics, 2020. CA Cancer J Clin 2020; 70(3): 145-64.

Vaughn CP, ZoBell SD, Furtado LV, Baker CL, Samowitz WS. Frequency of KRAS, BRAF, and NRAS mutations in colorectal cancer. Genes Chromosomes Cancer 2011; 50(5): 307-12.

Pang XL, Li QX, Ma ZP, Shi Y, Ma YQ, Li XX, Cui WL, Zhang W. Association between clinicopathological features and survival in patients with primary and paired metastatic colorectal cancer and KRAS mutation. Onco Targets Ther. 2017 May 19;10:2645-54.

Margonis GA, Kim Y, Spolverato G, Ejaz A, Gupta R, Cosgrove D, et al. Association between specific mutations in KRAS codon 12 and colorectal liver metastasis. JAMA Surgery 2015; 150(8): 722-9.

Li W, Liu Y, Cai S, Yang C, Lin Z, Zhou L, et al. Not all mutations of KRAS predict poor prognosis in patients with colorectal cancer. Int J Clin Exp Pathol 2019;12(3): 957-67.

Wolf WL, Ye F, Tran V, Yang Z, White R, Bloom K, et al. Sensitive multiplex detection of KRAS codons 12 and 13 mutations in paraffinembedded tissue specimens. J Clin Pathol. 2011; 64(1): 30-6.

Tol J, Dijkstra JR, Vink-Börger ME, Nagtegaal ID, Punt CJ, Van Krieken JH, et al. High sensitivity of both sequencing and real-time PCR analysis of KRAS mutations in colorectal cancer tissue. J Cell Mol Med 2010; 14(8): 2122-31.

Heinemann V, Stintzing S, Kirchner T, Boeck S, Jung A. Clinical relevance of EGFR- and KRAS-status in colorectal cancer patients treated with monoclonal antibodies directed against the EGFR. Cancer Treatment Reviews 2009; 35(3): 262-71.

Jones RP, Sutton PA, Evans JP, Clifford R, McAvoy A, Lewis J, et al. Specific mutations in KRAS codon 12 are associated with worse overall survival in patients with advanced and recurrent colorectal cancer. Br J Cancer 2017; 116(7): 923-9.

Passot G, Denbo JW, Yamashita S, Kopetz SE, Chun YS, Maru D, et al. Is hepatectomy justified for patients with mutant colorectal liver metastases? An analysis of 524 patients undergoing curative liver resection. Surgery 2017; 161(2): 332-40.